A 43-year-old company, Copan is leading world’s business for Covid-19 swab product. Just how many businesses are down hit by Covid-19? This does not affect Copan at all. This is a brief discussion of Copan’s most phenomenal swab invention!
Italy was one of the most infected country in Europe since the first wave. But exactly on January 2020 the peak season of Covid-19, Stefania Triva (Italian) chose a special material for swab. This one is a ‘flocked swab’ covered with tiny synthetic fibers resembling split ends. This new product differs from the most of swab product with regular cotton Q-tip.
Since then, Copan leads flocked swab standard globally. Why? Regular cotton Q-tip only releases 20% of the sample, while flocked swab quadrupled the sample to 80%. Four times more efficient and reliable than the regular swab. Next, Copan currently produces 1 billion swabs a year, with net income quintupled since 2020 with $372 million revenue. Her sales grow to reach $445 million.
Trivia however does not open public markets and refuses investments flowing to fund Copan. This is because Trivia is highly positive and confident that Copan is an independent and solid business that does not need to seek external funds. She can project that for the next year and forward, Copan would remain to belong in the company’s family business.
With the same swab material, Copan next aims at its use for forensic DNA from crime scenes. This allows Copan not only benefited from health but also security field. It gets more high tech. Copan’s lab automation processes urine tests and complex bacterial infections. Forbes said it can attain a much bigger market than just swab. Trivia adds that she continues to make innovations in automation that have revolutionized microbiology.
